top of page

Mycophenolate Mofetil

Grade

IMHA

Therapeutics

​

  1. Multimodal Use: -

  2. Adverse Effects Profile: Adverse Effects: Diarrhea, vomiting, and inappetence are the most frequently reported. Neutropenia is also possible (Fukushima et al., 2021)

  3. Reproductive Safety: -

  4. Treatment Goals: -

  5. Treatment Endpoints: -

  6. Efficacy Profile: -

  7. Alternative Products: -.

  8. Alternative Protocols: -

  9. Clinical Review:  No Delphi review has been performed. This is a pilot monograph.



Evidence

​

Mycophenolate Mofetil | Dog | Literature Review

  1. Fukushima, K., Lappin, M., Legare, M., Veir, J., 2021. A retrospective study of adverse effects of mycophenolate mofetil administration to dogs with immune‐mediated disease. J Vet Intern Med 35, 2215–2221. https://doi.org/10.1111/jvim.16209

  2. Goggs, R., 2020. Therapeutic Strategies for Treatment of Immune-Mediated Hemolytic Anemia. Vet Clin North Am Small Anim Pract 50, 1327–1349. https://doi.org/10.1016/j.cvsm.2020.07.010

  3. Grobman, M., Boothe, D.M., Rindt, H., Williamson, B.G., Katz, M.L., Coates, J.R., Reinero, C.R., 2017. Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. J Vet Pharmacol Ther 40, e1–e10. https://doi.org/10.1111/jvp.12420

  4. Kristiansen, P.S., Nielsen, L.N., 2021. Immunomodulatory and immunosuppressive drug protocols in the treatment of canine primary immune thrombocytopenia, a scoping review. Acta Vet Scand 63, 54. https://doi.org/10.1186/s13028-021-00620-z

  5. Lim, D., Jin, Y., Son, Y., Oh, T., Bae, S., 2022. A suspected case of a multiple autoimmune syndrome in a poodle dog. Vet Med Sci 8, 431–436. https://doi.org/10.1002/vms3.741

  6. Oggier, D., Tomsa, K., Mevissen, M., Glaus, T., 2018. [Efficacy of the combination of glucocorticoids, mycophenolate-mofetil and human immunoglobulin for the therapy of immune mediated haemolytic anaemia in dogs]. Schweiz Arch Tierheilkd 160, 171–178. https://doi.org/10.17236/sat00151

  7. Richter, P., Fischer, H., Dörfelt, R., 2021. Immunoadsorption in a dog with severe immune mediated hemolytic anemia. J Clin Apher 36, 668–672. https://doi.org/10.1002/jca.21913

  8. Rieder, J., Mischke, R., 2018. [Immunosuppressive therapy in dogs and cats. Properties of drugs and their use in various immune-mediated diseases]. Tierarztl Prax Ausg K Kleintiere Heimtiere 46, 105–118. https://doi.org/10.15654/TPK-180274

  9. Sollinger, H.W., 1995. Mycophenolate mofetil. Kidney Int Suppl 52, S14-17.

  10. Subgroup, I.C.G.S.G.E.P., Segev, G., Cowgill, L. d., Heiene, R., Labato, M. a., Polzin, D. j., 2013. Consensus Recommendations for Immunosuppressive Treatment of Dogs with Glomerular Disease Based on Established Pathology. Journal of Veterinary Internal Medicine 27, S44–S54. https://doi.org/10.1111/jvim.12228

  11. Swann, J.W., Garden, O.A., Fellman, C.L., Glanemann, B., Goggs, R., LeVine, D.N., Mackin, A.J., Whitley, N.T., 2019. ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs. J Vet Intern Med 33, 1141–1172. https://doi.org/10.1111/jvim.15463

  12. West, L.D., Hart, J.R., 2014. Treatment of idiopathic immune-mediated hemolytic anemia with mycophenolate mofetil in five dogs. J Vet Emerg Crit Care (San Antonio) 24, 226–231. https://doi.org/10.1111/vec.12121

Mycophenolate Mofetil | Dog | Expert Opinion

  1. 1317822* |  220805 Extrapolation of pharmacological properties in man and veterinary species. Some material employed in collating the data displayed here was taken from veterinary product datasheets or extrapolated from pharmacology texts.


Last Updated by 1317822* | on 221012


Monograph Details

​

bottom of page